Information Provided By: 
Fly News Breaks for April 13, 2015
SHPG
Apr 13, 2015 | 07:20 EDT
JPMorgan raised its price target for Shire to $288 after lifting its estimates for Lifitegrast in dry eye following the FDA's Priority Review designation. The firm believes the FDA is very likely to approve the application in October of this year, without waiting for the third Phase III study late 2015. It upped its 2020 Lifitegrast forecasts by $600M to $900M and reiterates an Overweight rating on Shire.
News For SHPG From the Last 2 Days
There are no results for your query SHPG
